Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration by Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík

“…Abstract Aim The aim of this study was to analyse the outcomes of patients with large B‐cell lymphoma (LBCL) treated with chimeric antigen receptor T‐cell therapy (CAR‐Tx), with a focus on outcomes after CAR T‐cell failure, and to define the risk factors for rapid progression and further treatment. …”
Get full text

Exploring new horizons in CAR-based therapy for the treatment of thyroid-associated ophthalmopathy by Xin-Yu Zhu, Wei-Yi Zhou, Tuo Li

Subjects: Get full text

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report by G. Menardi, A. Castellino, C. Castellino, M. E. Bersia, E. Grande, G. Fraternali, M. Massaia, C. Fruttero

“…The report underscores the complexities of chimeric antigen receptor T-cell treatment and sheds light on strategies employed to mitigate toxic effects. …”
Get full text

The impact of CD3ζ ITAM multiplicity and sequence on CAR T-cell survival and function by Shubhabrata Majumdar, Hilda Echelibe, Maria Bettini, Matthew L. Bettini

Subjects: “…chimeric antigen receptor (CAR)…”
Get full text

Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma by Yaya Chu, Meijuan Tian, Uksha Saini, Jessica Ayala-Cuesta, Kayleigh Klose, Alyssa S. Mendelowitz, Keira Foley, Mehmet F. Ozkaynak, Wen Luo, Timothy P. Cripe, Dean A. Lee, Kevin A. Cassady, Mitchell S. Cairo

Subjects: Get full text

Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy by Fatemeh Dehghan, Yekta Metanat, Mandana Askarizadeh, Ehsan Ahmadi, Vahid Moradi

Subjects: Get full text

Cellular therapies in rheumatic and musculoskeletal diseases by Pedro Franco-Fuquen, Juana Figueroa-Aguirre, David A. Martínez, Eider F. Moreno-Cortes, Juan E. Garcia-Robledo, Fabio Vargas-Cely, Daniela A. Castro-Martínez, Mustafa Almaini, Januario E. Castro

Subjects: Get full text

Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment by Liting Chen, Rongshan Huang, Chaoshuo Huang, Guiming Nong, Yuanyuan Mo, Lvyin Ye, Kunhong Lin, Anping Chen, Anping Chen

Subjects: Get full text

A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells by Zhao Zhang, Lianfeng Zhao, Tinghui Huang, Zhengliang Chen, Zhengliang Chen, Yaoyao Zhao, Yaoyao Zhao, Junqing Liang, Xudong Ao, Xiaoqiong Jia, Lei Kang, Linghui Kong, Qi Jing, Jianhua Hu, Lili Gu, Feiyan Pan, Zhigang Hu, Lingfeng He, Muya Zhou, Jiannan Chen, Zhigang Guo

Subjects: “…chimeric antigen receptor T (CAR-T)…”
Get full text

Nucleotide receptor P2X7/STAT6 pathway regulates macrophage M2 polarization and its application in CAR-T immunotherapy by Qin Si, Lu Yang, Jie Liu, Hui Liu, Ruifang Bu, Na Cui

Subjects: Get full text

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia by P. Joy Ho, Hang Quach, M. Hasib Sidiqi, M. Hasib Sidiqi, Cindy H. Lee, Jason Butler, Andrew Spencer, Kenneth Micklethwaite, Kenneth Micklethwaite, Kenneth Micklethwaite, Kenneth Micklethwaite, Jingya Li, Elissa Cusson, Robert Bagnall, Simon J. Harrison

Subjects: “…chimeric antigen receptor immunotherapy…”
Get full text

Biparatopic antibodies: therapeutic applications and prospects by David L. Niquille, Kyle M. Fitzgerald, Nimish Gera

Subjects: Get full text

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy by Anna De Lucia, Lucia Mazzotti, Lucia Mazzotti, Anna Gaimari, Anna Gaimari, Matteo Zurlo, Roberta Maltoni, Claudio Cerchione, Sara Bravaccini, Angelo Delmonte, Lucio Crinò, Patricia Borges de Souza, Luigi Pasini, Fabio Nicolini, Fabrizio Bianchi, Manel Juan, Hugo Calderon, Chiara Magnoni, Chiara Magnoni, Luca Gazzola, Luca Gazzola, Paola Ulivi, Massimiliano Mazza

Subjects: Get full text

Application of adoptive cell therapy in malignant melanoma by Qianrong Hu, Jiangying Xuan, Lu Wang, Kangjie Shen, Zixu Gao, Yuhong Zhou, Chuanyuan Wei, Jianying Gu

Subjects: Get full text

iPSC Technology Revolutionizes CAR-T Cell Therapy for Cancer Treatment by Jiepu Zong, Yan-Ruide Li

Subjects: Get full text

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis by Huyen Thi La, Dao Bich Thi Tran, Hai Manh Tran, Linh Trong Nguyen

“…This study designed the chimeric antigen receptor T-cell (CAR-T) to bind to the CD47 to inhibit the expression of CD47. …”
Get full text

Weal and woe of interleukin-18 in the T cell therapy of cancer by Christoph Kessel, Hinrich Abken, Claudia Rossig

“…Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. …”
Get full text

Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases by Qiaolin Huang, Xiaojian Zhu, Yicheng Zhang

“…Abstract Adoptive immunotherapy using engineered T cells expressing chimeric antigen receptors has shown remarkable success in treating patients with hematological malignancies. …”
Get full text

Tumor-induced metabolic immunosuppression: Mechanisms and therapeutic targets by Jean-Ehrland Ricci

“…This review highlights the regulation of antitumor immune responses through metabolic reprogramming in cancer and immune cells and explores therapeutic strategies that target these metabolic pathways in cancer immunotherapy, including using chimeric antigen receptor (CAR)-T cells. We discuss innovative combinations of immunotherapy, cellular therapies, and metabolic interventions that could optimize the efficacy of existing treatment protocols.…”
Get full text

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity by Yaojie Kong, Jingyao Li, Xueyao Zhao, Yanwei Wu, Liang Chen

“…Chimeric Antigen Receptor (CAR)-T cell therapy has rapidly emerged as a groundbreaking approach in cancer treatment, particularly for hematologic malignancies. …”
Get full text